ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares

Key Points

• ANI VP Meredith Cook sold 500 shares on April 13 at an average price of $77.95 under a pre-arranged Rule 10b5-1 plan, reducing her stake by 0.63% to 78,890 shares valued at roughly $6.15 million; she also sold 500 shares each on March 13 and January 13.
• ANIP was trading near $78.31 with a market cap of $1.76 billion, a P/E of 23.31, a 12‑month range of $56.71–$99.50, and 50/200-day moving averages of $76.38 and $82.35 respectively.
• The stock carries a consensus rating of “Moderate Buy” with an average target of $107.33, while analysts’ views vary (e.g., Guggenheim raised its target to $124 and Zacks cut to a hold) and institutional ownership stands at about 76.05% with recent new/added stakes by firms like Jane Street and Norges Bank.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of the business's stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $77.95, for a total value of $38,975.00. Following the sale, the vice president owned 78,890 shares of the company's stock, valued at approximately $6,149,475.50. This trade represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Friday, March 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $72.62, for a total value of $36,310.00.
• On Tuesday, January 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $84.33, for a total value of $42,165.00.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP traded down $0.05 during mid-day trading on Monday, hitting $78.31. The stock had a trading volume of 274,106 shares, compared to its average volume of 425,657. The firm's 50 day moving average is $76.38 and its 200 day moving average is $82.35. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 23.31 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a twelve month low of $56.71 and a twelve month high of $99.50.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ANIP shares. Guggenheim boosted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. Zacks Research downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, January 6th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, March 14th. Finally, Weiss Ratings restated a "hold (c+)" rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $107.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ANIP. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals during the first quarter worth about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock valued at $736,000 after buying an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock valued at $3,235,000 after buying an additional 423 shares during the period. Jane Street Group LLC acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $2,706,000. Finally, Norges Bank purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $625,000. Institutional investors and hedge funds own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.